PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.

Clinical trial NCT07410520 · RECRUITING

Trial details

NCT number: NCT07410520
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Primary Central Nervous System Lymphoma (PCNSL)Secondary Central Nervous System Lymphoma (SCNSL)

Start date: 2026-02-07
Primary completion: 2028-12-31
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.